146 related articles for article (PubMed ID: 35585020)
21. MRI background parenchymal enhancement in patients with invasive lobular carcinoma: Endocrine hormonal treatment effect.
Grubstein A; Rapson Y; Manor M; Yerushalmi R; Gavrieli S; Tamir S; Meshulam S; Atar E; Stemmer SM; Shochat T; Allweis TM
Breast Dis; 2022; 41(1):317-323. PubMed ID: 35786645
[TBL] [Abstract][Full Text] [Related]
22. Does breast MRI background parenchymal enhancement indicate metabolic activity? Qualitative and 3D quantitative computer imaging analysis.
Mema E; Mango VL; Guo X; Karcich J; Yeh R; Wynn RT; Zhao B; Ha RS
J Magn Reson Imaging; 2018 Mar; 47(3):753-759. PubMed ID: 28646614
[TBL] [Abstract][Full Text] [Related]
23. Contralateral parenchymal enhancement on breast MRI before and during neoadjuvant endocrine therapy in relation to the preoperative endocrine prognostic index.
Ragusi MAA; Loo CE; van der Velden BHM; Wesseling J; Linn SC; Beets-Tan RG; Elias SG; Gilhuijs KGA
Eur Radiol; 2020 Dec; 30(12):6740-6748. PubMed ID: 32691100
[TBL] [Abstract][Full Text] [Related]
24. Bilateral asymmetry of quantitative parenchymal kinetics at ultrafast DCE-MRI predict response to neoadjuvant chemotherapy in patients with HER2+ breast cancer.
Ren Z; Pineda FD; Howard FM; Fan X; Nanda R; Abe H; Kulkarni K; Karczmar GS
Magn Reson Imaging; 2023 Dec; 104():9-15. PubMed ID: 37611646
[TBL] [Abstract][Full Text] [Related]
25. Background parenchymal enhancement on breast MRI: association with recurrence-free survival in patients with newly diagnosed invasive breast cancer.
Lim Y; Ko ES; Han BK; Ko EY; Choi JS; Lee JE; Lee SK
Breast Cancer Res Treat; 2017 Jun; 163(3):573-586. PubMed ID: 28349273
[TBL] [Abstract][Full Text] [Related]
26. Background Parenchymal Enhancement of the Contralateral Normal Breast: Association with Tumor Response in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy.
Chen JH; Yu HJ; Hsu C; Mehta RS; Carpenter PM; Su MY
Transl Oncol; 2015 Jun; 8(3):204-9. PubMed ID: 26055178
[TBL] [Abstract][Full Text] [Related]
27. Prognostic value of response evaluation based on breast MRI after neoadjuvant treatment: a retrospective cohort study.
Bitencourt AGV; Pires BS; Calsavara VF; Negrão EMS; Souza JA; Graziano L; Guatelli CS; Makdissi FB; Sanches SM; Tavares MC; Osório CABT; De Brot M; Marques EF; Chojniak R
Eur Radiol; 2021 Dec; 31(12):9520-9528. PubMed ID: 34036420
[TBL] [Abstract][Full Text] [Related]
28. Impact of radiotherapy on background parenchymal enhancement in breast magnetic resonance imaging.
Kim YJ; Kim SH; Choi BG; Kang BJ; Kim HS; Cha ES; Song BJ
Asian Pac J Cancer Prev; 2014; 15(7):2939-43. PubMed ID: 24815428
[TBL] [Abstract][Full Text] [Related]
29. Ki-67 as a controversial predictive and prognostic marker in breast cancer patients treated with neoadjuvant chemotherapy.
Ács B; Zámbó V; Vízkeleti L; Szász AM; Madaras L; Szentmártoni G; Tőkés T; Molnár BÁ; Molnár IA; Vári-Kakas S; Kulka J; Tőkés AM
Diagn Pathol; 2017 Feb; 12(1):20. PubMed ID: 28222768
[TBL] [Abstract][Full Text] [Related]
30. Survival is associated with complete response on MRI after neoadjuvant chemotherapy in ER-positive HER2-negative breast cancer.
Loo CE; Rigter LS; Pengel KE; Wesseling J; Rodenhuis S; Peeters MJ; Sikorska K; Gilhuijs KG
Breast Cancer Res; 2016 Aug; 18(1):82. PubMed ID: 27495815
[TBL] [Abstract][Full Text] [Related]
31. Multiparametric
Leithner D; Helbich TH; Bernard-Davila B; Marino MA; Avendano D; Martinez DF; Jochelson MS; Kapetas P; Baltzer PAT; Haug A; Hacker M; Tanyildizi Y; Morris EA; Pinker K
J Nucl Med; 2020 Jan; 61(1):20-25. PubMed ID: 31253745
[TBL] [Abstract][Full Text] [Related]
32. Association of breast cancer with MRI background parenchymal enhancement: the IMAGINE case-control study.
Watt GP; Sung J; Morris EA; Buys SS; Bradbury AR; Brooks JD; Conant EF; Weinstein SP; Kontos D; Woods M; Colonna SV; Liang X; Stein MA; Pike MC; Bernstein JL
Breast Cancer Res; 2020 Dec; 22(1):138. PubMed ID: 33287857
[TBL] [Abstract][Full Text] [Related]
33. Amount of fibroglandular tissue FGT and background parenchymal enhancement BPE in relation to breast cancer risk and false positives in a breast MRI screening program : A retrospective cohort study.
Vreemann S; Dalmis MU; Bult P; Karssemeijer N; Broeders MJM; Gubern-Mérida A; Mann RM
Eur Radiol; 2019 Sep; 29(9):4678-4690. PubMed ID: 30796568
[TBL] [Abstract][Full Text] [Related]
34. Quantitative background parenchymal enhancement and fibro-glandular density at breast MRI: Association with BRCA status.
Goodburn R; Kousi E; Sanders C; Macdonald A; Scurr E; Bunce C; Khabra K; Reddy M; Wilkinson L; O'Flynn E; Allen S; Schmidt MA
Eur Radiol; 2023 Sep; 33(9):6204-6212. PubMed ID: 37017702
[TBL] [Abstract][Full Text] [Related]
35. Quantitative Measures of Background Parenchymal Enhancement Predict Breast Cancer Risk.
Niell BL; Abdalah M; Stringfield O; Raghunand N; Ataya D; Gillies R; Balagurunathan Y
AJR Am J Roentgenol; 2021 Jul; 217(1):64-75. PubMed ID: 32876474
[No Abstract] [Full Text] [Related]
36. Breast MRI background parenchymal enhancement as an imaging bridge to molecular cancer sub-type.
Dilorenzo G; Telegrafo M; La Forgia D; Stabile Ianora AA; Moschetta M
Eur J Radiol; 2019 Apr; 113():148-152. PubMed ID: 30927939
[TBL] [Abstract][Full Text] [Related]
37. Breast MRI phenotype and background parenchymal enhancement may predict tumor response to neoadjuvant endocrine therapy.
Hilal T; Covington M; Kosiorek HE; Zwart C; Ocal IT; Pockaj BA; Northfelt DW; Patel BK
Breast J; 2018 Nov; 24(6):1010-1014. PubMed ID: 30066421
[TBL] [Abstract][Full Text] [Related]
38. Association between MRI background parenchymal enhancement and lymphovascular invasion and estrogen receptor status in invasive breast cancer.
Li J; Mo Y; He B; Gao Q; Luo C; Peng C; Zhao W; Ma Y; Yang Y
Br J Radiol; 2019 Nov; 92(1103):20190417. PubMed ID: 31398071
[TBL] [Abstract][Full Text] [Related]
39. Response Predictivity to Neoadjuvant Therapies in Breast Cancer: A Qualitative Analysis of Background Parenchymal Enhancement in DCE-MRI.
La Forgia D; Vestito A; Lasciarrea M; Comes MC; Diotaiuti S; Giotta F; Latorre A; Lorusso V; Massafra R; Palmiotti G; Rinaldi L; Signorile R; Gatta G; Fanizzi A
J Pers Med; 2021 Apr; 11(4):. PubMed ID: 33915842
[TBL] [Abstract][Full Text] [Related]
40. Microcalcifications and Peritumoral Edema Predict Survival Outcome in Luminal Breast Cancer Treated with Neoadjuvant Chemotherapy.
Kwon BR; Shin SU; Kim SY; Choi Y; Cho N; Kim SM; Yi A; Yun B; Jang M; Ha SM; Lee SH; Chang JM; Moon WK
Radiology; 2022 Aug; 304(2):310-319. PubMed ID: 35536129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
